Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy
Advanced Science · 2025-10 · 12 (40)
DOI: 10.1002/advs.202513567 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 12.09.2025. Verfasst von Qianqian Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Pharmacy College, Shaanxi University of Chinese Medicine, Xian…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunotherapy, Neoplasms, Nanomedicine. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 269 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Projects of Xizang Axtonomoxs Region, China, the Fundamental of Research Funds for the Central Universities..
Abstract (Originalsprache)
Immunotherapy has emerged as a transformative paradigm in oncology, yet its clinical efficacy remains constrained by the immunosuppressive tumor microenvironment and inadequate spatiotemporal control of existing modalities, resulting in suboptimal patient response rates and frequent immune‐related adverse events. Stimuli‐responsive biomaterials, capable of precise modulation over the delivery kinetics of immunotherapeutic agents, are validated as powerful strategies for achieving targeted immunomodulation. This review systematically delineates innovative design frameworks for tumor microenvironment (TME)‐responsive nanomaterials leveraging dynamic TME features. Through detailed dissection of cancer‐immunity cycle barriers, including spanning impaired antigen presentation, compromised T cell priming/activation, and defective effector function, breakthrough advances in next‐generation delivery platforms are highlighted that reignite antitumor immunity at a critical juncture. Furthermore, preclinical validation and clinical translation challenges of TME‐responsive nanomaterials are evaluated. Building upon current immunotherapy trends, this review also identifies critical translational determinants, with the aim of bridging the bench‐to‐bedside gap in precision cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Pharmacy College, Shaanxi University of Chinese Medicine, Xianyang, 712046, China.
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Key Laboratory of Leather Chemistry and Engineering (Ministry of Education), West China School of Pharmacy, Sichuan University, Chengd…
- Tianfu Jincheng Laboratory, Chengdu, 610093, China.
- Institute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, Uzbekistan.
- Medical College of Tibet University, Lasa, 850002, China.
Förderung
- Science and Technology Projects of Xizang Axtonomoxs Region, China
- the Fundamental of Research Funds for the Central Universities.
Zitieren
APA
Huang, Q., Tong, F., Chen, J., Kayumov, M., Lv, Y., Shi, Y., Ye, B., & Gao, H. (2025). Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy. Advanced Science, 12(40). https://doi.org/10.1002/advs.202513567
Vancouver
Huang Q, Tong F, Chen J, Kayumov M, Lv Y, Shi Y, et al. Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy. Advanced Science. 2025;12(40). doi:10.1002/advs.202513567
BibTeX
@article{Huang2025,
author = {Huang, Qianqian and Tong, Fan and Chen, Jiantao and Kayumov, Muzaffar and Lv, Yue and Shi, Yajun and Ye, Bengui and Gao, Huile},
title = {Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {40},
doi = {10.1002/advs.202513567}
}
EUVIMED